
Retinal angiomatous proliferation (RAP) lesions, treatment with ranibizumab, the absence of subretinal fluid, and the absence of subretinal pigment epithelium fluid (RPE) were associated with fewer injections for neovascular age-related macular degeneration (AMD) among participants from the Comparison of AMD Treatments Trials (CATT), said Daniel F. Martin, MD.
